Taro Pharm Inds (TARO) 125.95 $TARO Taro Provides

New Post Public Reply Private Reply Replies (0) Message Board

Sep 7, 2016 at 3:08 AM

Taro Pharm Inds (TARO) 125.95 $TARO

Taro Provides Results for Quarter Ended June 2016
BusinessWire - Wed Aug 10, 4:12PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"

today provided unaudited financial results for the quarter ended June 30, 2016.
TARO: 125.95 (-0.42)

Taro to Announce First Quarter Results on August 10, 2016
BusinessWire - Tue Aug 02, 4:00PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2016, after the close of market on Wednesday, August 10, 2016.
TARO: 125.95 (-0.42)

Taro Announces Resignation of Chief Financial Officer
BusinessWire - Tue Jun 21, 4:20PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company"

announced today that it has accepted the resignation of its Chief Financial Officer, Michael Kalb, effective June 29, 2016. Mr. Kalb is leaving to accept the position of CFO at another public company.
TARO: 125.95 (-0.42)

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2016
BusinessWire - Thu Jun 09, 4:16PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO, "Taro"

announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2016, filed with the Securities and Exchange Commission (the "SEC"

, is available within the Investor Relations section of Taro's website at www.taro.com.
TARO: 125.95 (-0.42)

Taro Provides Results for Year Ended March 31, 2016
BusinessWire - Thu May 26, 5:33PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"

today provided unaudited financial results for the quarter and year ended March 31, 2016.
TARO: 125.95 (-0.42)

Taro to Announce Results for Year Ended March 31, 2016 on May 26, 2016
BusinessWire - Fri May 20, 3:14PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the year ended March 31, 2016, on Thursday, May 26, 2016.
TARO: 125.95 (-0.42)

Taro to Make Keveyis(TM) Available to Distributors Free of Cost
BusinessWire - Mon May 02, 7:59AM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"

today announced that its U.S. subsidiary, Taro Pharmaceuticals U.S.A., Inc., will now make Keveyis(TM) (dichlorphenamide) available to distributors at no cost for the treatment of primary periodic paralysis, an ultra-rare and debilitating disease. As a result, Taro will cease commercial sales and related promotional activities for Keveyis and bear all costs associated with its manufacture. In the near term, patients will continue to receive the medicine through Diplomat as the Company evaluates the best option for keeping pharmacy dispensing fees to patients as low as possible.
TARO: 125.95 (-0.42)

American CryoStem Corporation Retains Investor Relations Partners as Investor Relations Counsel
Marketwired - Fri Apr 01, 7:00AM CDT
American CryoStem Corporation (OTC PINK: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has retained Investor Relations Partners (IRP) to expand the Company's strategic investor relations program.
TARO: 125.95 (-0.42), HOT: 76.48 (-0.70)

Taro posts 3Q profit
Automated Insights - Wed Feb 10, 4:33PM CST
HAIFA BAY, Israel (AP) _ Taro Pharmaceutical Industries Ltd. (TARO) on Wednesday reported fiscal third-quarter profit of $189 million.
TARO: 125.95 (-0.42)

Taro Provides Results for December 31, 2015
BusinessWire - Wed Feb 10, 4:15PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"

today provided unaudited financial results for the three and nine months ended December 31, 2015.
TARO: 125.95 (-0.42)

CORRECTING and REPLACING Taro to Announce Third Quarter Results on February 10, 2016
BusinessWire - Wed Feb 03, 1:57PM CST
The date at the end of the first paragraph of release dated February 2, 2016 should read: Wednesday, February 10, 2016 (instead of Tuesday, February 10, 2016).
TARO: 125.95 (-0.42)

Taro to Announce Third Quarter Results on February 10, 2016
BusinessWire - Tue Feb 02, 2:56PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2015, after the close of market on Tuesday, February 10, 2016.
TARO: 125.95 (-0.42)

Taro Provides Results for September 30, 2015
BusinessWire - Tue Nov 03, 5:06PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"

today provided unaudited financial results for the three and six months ended September 30, 2015.
TARO: 125.95 (-0.42)

Taro to Announce Second Quarter Results on November 3, 2015
BusinessWire - Tue Oct 27, 3:53PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2015, on Tuesday, November 3, 2015, after the close of the Market.
TARO: 125.95 (-0.42)

Taro Pharmaceutical Industries introduces Keveyis 50 mg tablets for treating primary hyperkalemic and hypokalemic periodic paralysis
M2 - Tue Sep 22, 3:16AM CDT
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) disclosed on Monday the launch of Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants in the US market.
TARO: 125.95 (-0.42)

Taro's Keveyis(TM) (dichlorphenamide) 50 mg Tablets Now Available for the Treatment of Primary Hyperkalemic and Hypokalemic Periodic Paralysis
BusinessWire - Mon Sep 21, 12:28PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that Keveyis(TM) (dichlorphenamide) 50 mg Tablets, the first medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants, is now available for appropriate patients through its specialty pharmacy partner, Diplomat. Periodic paralysis is a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.[1] It is estimated to affect approximately 5,000 people in the United States, up to 70 percent of which are currently undiagnosed.[2]
TARO: 125.95 (-0.42)

Taro Pharmaceutical Industries wins US FDA approval for Keveyis 50 mg tablets for treating primary hyperkalemic and hypokalemic periodic paralysis
M2 - Tue Aug 11, 4:47AM CDT
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) revealed on Monday the receipt of the US Food and Drug Administration's (FDA) approval for Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis.
TARO: 125.95 (-0.42)

FDA Approves Taro's Keveyis(TM) (dichlorphenamide) 50 mg Tablets for Primary Hyperkalemic and Hypokalemic Periodic Paralysis
BusinessWire - Mon Aug 10, 7:30AM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that the U.S. Food and Drug Administration (FDA) has approved Keveyis(TM) (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis [1]. Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States [2].
TARO: 125.95 (-0.42)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ETERC's Ele Aims to Revolutionize STEM Education for All

The AI Mentor Battleground in Education Ever found yourself wondering how public schools could step up their game without dumping money down the tech rabbit hole? ETERC’s latest push with Ele may just be a game-changer for them. We're not talking about your run-of-the-mill chatbot regurgitating facts from the internet—this is an AI tricked out for personalized...

Buffett Steps Down, New Faces at Berkshire Hathaway

End of an Era: Warren Buffett's Retirement Warren Buffett—there's a name that's echoed through the halls of investment for decades. Today, he's pulling down the curtain as Chairman of Berkshire Hathaway (NYSE: BRK). No fanfare, just a nod to the inevitable with his classic, humor-tinged confession: 'Father Time always wins.' Can’t argue with the man who’s seen the...

Kobold Press Explores Roleplaying as Literacy Tool

Gaming Illuminates Pathways to Literacy and Community Trust me, when an indie game publisher like Kobold Press makes waves, it's worth paying attention. They've carved a niche in the roleplaying world by marrying traditional game elements with valuable educational tools. The thrill of the game goes beyond rolling dice; it's a ticket to improving literacy, arithmetic, and...

California Accelerates AI Law with Newsom's Bold Move

Pushing AI Regulations into High Gear I'll tell you what—it's about time somebody shook things up in the AI world with more than empty promises. Governor Newsom's executive order is doing just that, fast-tracking the timeline for implementing California's SB 813. This move is like giving speed boots to the legislative process, revving up the rules to ensure AI doesn't...

Heafner Takes Helm at HGTC Amid Strategic Shifts

A New Era for HGTC with Dr. Heafner at the Wheel Out of the frying pan and into the fire—Dr. Lori Heafner is stepping up to lead Horry-Georgetown Technical College (HGTC) with a clean slate and a hefty load of responsibility come January 2027. After enduring an intense national search by the Area Commission, she beat out tough competition to earn the role. It's not just...

Debt Crisis Looms: Social Security at Risk

Debt Reality: A National Concern with Global Implications When it comes to the U.S. federal debt situation, the latest report from the National Seniors Policy Center is lighting a fire like no other, warning us that we're not crying wolf here. We've got fiscal numbers that may not sit well at breakfast. With roughly 67 cents of every new buck Uncle Sam borrows going to...

Vetology Reinvents AI Models for Veterinary Radiology

Revamping AI in Veterinary Practices Out there in San Diego, Vetology's been rolling up its sleeves and getting down to brass tacks with a complete do-over of their AI classifiers. They’ve rebuilt all 94 of them, every last one, on a brand-new architecture. No small task, this overhaul stretched from June to August and it wasn't just paint and polish but a whole new...

Ensuring Your Radon Mitigation System Stays Effective

Radon Mitigation: A Critical Measure for Home Safety Homeowners, you're probably aware of the ticking health time bomb known as radon. Not just an annoying gas, this colorless, odorless beast lurks quietly, threatening family health if not managed right. Mitch Kelley, a specialist in radon testing with Basement Solutions in Mankato, Minnesota, lays out a no-fuss guide to...

Calavera NY Website Revamp: Gemstone Expansion Hits

Calavera New York's Bold Online Makeover When a jewelry brand that's all about slashing retail markups makes a move this big, it's worth a real close-up look. Calavera New York, a name buzzing in the diamond and gemstone scene, just dropped a redesigned website that’s turning more than a few heads. They’re known for cutting out the middleman, a strategy that already...

DAHON's Tech: Crafting Folders That Ride Like Road Bikes

The Folding Bike Revolution: More Than Just a Fad You've seen them zipping around—those compact, folding bikes. They're not just for urban commuters looking to save space. Oh no, this is a full-blown cycling revolution we're talking about. DAHON, a name that's been rolling since 1982, has been riding these waves and making strides that others can only dream of. While...